Morphotek(R), Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer

EXTON, Pa., March 23 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced today that the U.S. Food and Drug Administration (FDA) has agreed to and approved the design of a single, pivotal, Phase III clinical trial evaluating farletuzumab (also known a...

Teikoku Pharma USA and Eisai Co., Ltd. Announce Licensing Agreement for a New 7-Day Transdermal Formulation of Donepezil.

SAN JOSE, Calif., March 9 /PRNewswire/ -- Teikoku Pharma USA Inc., the international specialty pharmaceutical company, announces that it has signed an exclusive worldwide (excluding Japan) licensing agreement with Eisai Co., Ltd. to develop and commercialize a new transdermal formulation of donepe...

Life Beyond Cancer Women's Retreat Calls for Applications

...3 at the Miraval luxury resort in Catalina, Ariz., is offered at an extremely affordable cost thanks to many sponsors including Platinum Sponsor eisai , Gold Sponsors Abraxis Oncology and Miraval luxury resort, Silver Sponsor James Lasker, MD , and contributor BAG IT , but space is ext...

Morphotek(R), Inc. Announces FDA Acceptance of Investigational New Drug Application for MORAb-004, a Monoclonal Antibody for the Treatment of Solid Tumors

...PRNewswire/ -- Morphotek(R), Inc., a subsidiary of eisai Corporation of North America, announced that the U...t Morphotek Morphotek(R), Inc., a subsidiary of eisai Corporation of North America, is a biopharmaceutic...n, please visit www.morphotek.com . About eisai Corporation of North America ...

Call for Nominations for the 2009 C.A.R.E. Pharmacy Award

... eisai Inc. and the Alzheimer's Association Support Award... WOODCLIFF LAKE, N.J., June 1 /PRNewswire/ -- eisai Inc., in coordination with the Alzheimer's Associa...is unwavering," said Cynthia Schwalm, President of eisai Inc. "We recognize the integral role that communi...

Experts Urge Family Members and Friends to Seek Immediate Intervention for Their Loved Ones Who May Have Alzheimer's Disease (AD)

...gns of AD are suspected. The ADSDG is sponsored by eisai Inc. and Pfizer Inc. Currently only 60 perce...al to nearly six million AD patients in the U.S. - eisai Inc. and Pfizer Inc worked with the ADSDG on the d...a multi-disciplinary panel of experts sponsored by eisai Inc. and Pfizer Inc that first convened in Novembe...

NORD to Honor Rare Disease Pioneers

...r acute bleeding episodes in patients with congenital fibrinogen deficiency, an extremely rare, potentially life-threatening bleeding disorder eisai Inc., for bringing to the patient community Banzel(TM), a much-needed treatment alternative for seizures linked to Lennox-Gastaut syndrome, a severe f...

NewCardio Elects Michael E. Hanson to Board of Directors

...y. From 1998 to 2001, he was a member of the board of directors, compensation and audit committees, of MGI Pharma, Inc., which was later purchased by eisai Pharmaceuticals. Mr. Hanson also serves on the board of directors of Z-92 Pharma and Elcos, Inc., and is also a member of Pearl Street Ventures, a ve...

SuperGen Reports 2008 Fourth Quarter and Year-End Financial Results

...pursuant to the license agreement entered into with MGI PHARMA (acquired by eisai Corporation of North America in January 2008) during 2004, which granted MG... forward-looking statements include, but are not limited to, the ability of eisai to generate global sales of Dacogen, risks and uncertainties related to the...

Eisai and Bial Announce Partnership Agreement for the European Commercialisation of the Novel Once Daily Anti-Epileptic Zebinix(R)

...ON, February 19 /PRNewswire-FirstCall/ -- - eisai Set to Become an Emerging Leader in the Treatment of Epilepsy eisai Europe Ltd (London; Chairman & CEO Yutaka Tsuchiya), the European subsidiary of eisai Co., Ltd. (Tokyo, President & CEO: Haruo Naito...

Eisai in Medical Technology

Materia Licenses Metathesis Catalyst Platform to Eisai

PASADENA, Calif.--(BUSINESS WIRE)--Jun 20, 2007 - Materia, Inc., a catalyst technology company, announced today the licensing of its metathesis platform to Eisai Co., Ltd., a leading Japanese pharmaceutical company, for use in drug discovery and development. The non-exclusive license agreement prov...

FDA Accepts sNDA for Alternative Dosing Regimen for Dacogen(R) (decitabine for injection) to Treat Patients with Myelodysplastic Syndromes (MDS)

... WOODCLIFF LAKE, N.J., July 8 /PRNewswire/ -- eisai Corporation of North America today announced that ...eview process," said Cynthia Schwalm, President of eisai Inc. "This application is one part of a full compl...om for full prescribing information. About eisai Corporation of North America ...

Current Status of the Development Programs of New Indications and Formulations for Aricept(R) for Enhancing Patient Value

...O and WOODCLIFF LAKE, N.J., July 2 /PRNewswire/ -- eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") and eisai Corporation of North America (Headquarters: Woodcl...ease. As progress in those programs has been made, eisai announces the status as follows: 1. Sustaine...

Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)

...tion. Under the terms of a deal with BIAL, announced in February this year, eisai Europe Ltd received a sole license to market, promote and distribute ESL within Europe**. eisai and BIAL plan to launch Zebinix(R) across Europe during 2009 and into 2010,...

Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes

... which enables RAD1901 to function as an estrogen agonist within the central nervous system and thereby relieve hot flashes. RAD1901 was discovered by eisai Co., Ltd. and licensed by Radius (excluding Japan) in 2006. About Vasomotor Symptoms (Hot Flashes) Hot flashes are a common symptom during ...

Micromet Key Events for 2009

...mune diseases, is expected to start a first clinical phase 1 trial in mid 2009; -- MT228, a glycolipid binding human antibody in development by eisai for the treatment of melanoma, is expected to start a first phase 1 clinical trial in 2009; -- MT293, a humanized monoclonal antibody targeting...

FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation

... WOODCLIFF LAKE, N.J., Dec. 14 /PRNewswire/ -- eisai Corporation of North America today announced that ... adult patients," said Cynthia Schwalm, President, eisai Inc. "With the approval of Lusedra, Eisai continue...w.eisai.com/presskit.asp?ID=217 . About eisai Corporation of North America ...

Dacogen(R) (decitabine for injection) Data Presented on a Phase II Clinical Trial in Elderly Patients with Acute Myeloid Leukemia (AML)

...ses SAN FRANCISCO, Dec. 8 /PRNewswire/ -- eisai Corporation of North America today announced data ..., Oncology & Institutional Care Business Unit, eisai Inc. "The data presented today support our commit... for full prescribing information. About eisai Corporation of North America ...

First Ever Study on Alzheimer's Disease Treatment in Hispanics Presented at Major Medical Meeting

...ty Groups CHICAGO, July 30, 2008 /PRNewswire/ -- eisai Inc. and Pfizer Inc (NYSE: PFE) announced today re...line memory screener. The EARTH study represents eisai and Pfizer's leadership in understanding the benef...99-9616 or visit http://www.aricept.com . About eisai Inc. ...

Controversy About Lack of Placebo Group Decline in Alzheimer's Clinical Trials

...r Alzheimer's between 1990 and 1999. The work stemmed from discussions and analyses undertaken through an expert working group initiated and funded by eisai and Pfizer, makers and marketers of donepezil. "Our results indicate that patients with Alzheimer's entering the later clinical trials appear to be ...

Eisai in Medical Dictionary

Expectorant

...) are treated with expectorants that loosen mucus from the ... Expectorants ... Information about expectorant in the free online English ... eisai Launches New OTC Antituissive Expectorant ASTHPHYLLIN S Tablets by JCNN News Summaries ... Comprehensive and trusted information about Hycotuss ...

Eisai in Biological News

Eisai announces Phase II data on E7389, a potential new therapy for the treatment of breast cancer

...PhD, Associate Vice President and Global Therapeutic Area Head, Oncology at eisai Medical Research Inc. "E7389 is an example of Eisai's human health care (hh...) commitment to satisfy unmet medical needs of patients and their families. eisai has targeted oncology/critical care as one of three key therapeutic areas o...

Eisai in Biological Technology

Eisai Corporation of North America Announces Appointment of Cynthia Schwalm as President, Eisai Inc.

WOODCLIFF LAKE, N.J., May 5 /PRNewswire/ -- Eisai Corporation of North America today announces the immediate appointment of Cynthia Schwalm as President of Eisai Inc. In her new role, Ms. Schwalm will have full operating responsibility for leading Eisai Inc., the U.S. commercial operation of E...

TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimer's Disease

LA JOLLA, Calif., Sept. 25 /PRNewswire-FirstCall/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) today announced a one year extension of its research agreement with Eisai Co., Ltd. that was entered into on October 1, 2005. The extension marks the continuation of Eisai's support of Alzheime...

TorreyPines Therapeutics Sells Alzheimer's Disease Genetics Program to Eisai

LA JOLLA, Calif., Nov. 10 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) today announced that it has agreed to sell its Alzheimer's disease genetics research program to Eisai Co., Ltd. for an upfront cash payment. TorreyPines and Eisai have collaborated on the genetics program...

Morphotek(R), Inc. and Cancer Innovations, Inc. Announce Evaluation and Option Agreement for Therapeutic Monoclonal Antibodies

...Newswire/ -- Morphotek((R)), Inc., a subsidiary of eisai Corporation of North America, and Cancer Innovatio...rphotek Morphotek((R)), Inc., a subsidiary of eisai Corporation of North America, is a biopharmaceutic...ease visit www.morphotek.com . About eisai Corporation of North America ...

New Report Just Published: World Prostate Cancer Therapeutics Market Report

...r from Applera Corporation II-69 GPC Biotech and Celgene Terminate Agreement for Satraplatin II-70 EUSA Acquires Cytogen Corporation II-70 eisai Acquires MGI Pharma II-70 BN ImmunoTherapeutics Enters into a Scientific Partnership with NCI II-70 Morphotek(R) Enters into Licensing Agr...

Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease

...PRNewswire/ -- Morphotek(R), Inc., a subsidiary of eisai Corporation of North America, announced a research...t Morphotek Morphotek(R), Inc., a subsidiary of eisai Corporation of North America, is a biopharmaceutic...ion, please visit www.morphotek.com . About eisai Corporation of North America ...

Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement

...PRNewswire/ -- Morphotek(R), Inc., a subsidiary of eisai Corporation of North America, and Lonza Group Ltd ...t Morphotek Morphotek(R), Inc., a subsidiary of eisai Corporation of North America, is a biopharmaceutic...ion, please visit www.morphotek.com . About eisai Corporation of North America ...

New Survey Reveals Gap in Understanding of Alzheimer's Disease Risk and Prevention Among Most Vulnerable Populations

...n Richardson, vice president of Medical Affairs at eisai Inc. presented these findings last week at the 200...education and increased access to screening." eisai conducted the research to learn more about the per...ss to care," said Lonnel Coats, president and COO, eisai Corporation of North America. "We commend the CBC...

Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments

... Development and Commercialization of Therapeutic Antibodies for Oncology and Immunology In March 2009, HGS and Morphotek, Inc., a subsidiary of eisai Corporation of North America, entered into a collaboration to discover, develop and commercialize therapeutic monoclonal antibodies in the fields of o...

Novel Once Daily Anti-Epileptic Zebinix(R) Approved in the European Union

...ortugal, President & CEO Dr Luis Portela), and eisai Europe Limited (London; Chairman & CEO Yutaka Tsuchiya), the European subsidiary of eisai Co., Ltd. (Tokyo, President & CEO: Haruo Naito...l. "We will work closely with our European partner eisai to launch Zebinix(R) across the EU during 2009 and...